Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3432
- Pages: 239
-
Format:
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics that is majorly used to treat bacterial infections. It resembles penicillin and hence, is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea.
The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies, and rise in prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in the untapped market are anticipated to provide potential opportunities for the market growth.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of market trends, macro-economic indicators, and governing factors.
This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 20172025 that helps identify the upcoming market opportunities.
Recent industry trends and developments and the future opportunities are also covered.
Extensive knowledge about the key market players and their strategies is provided.
Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.
Key Market Segments
By Generation
o First-generation Cephalosporin
o Second-generation Cephalosporin
o Third-generation Cephalosporin
o Fourth-generation Cephalosporin
o Fifth-generation Cephalosporin
By Type
o Branded
o Generics
By Route of Drug Administration
o Injection
o Oral
By Application
o Respiratory Tract Infection
o Skin Infection
o Ear Infection
o Urinary Tract Infection
o Sexually Transmitted Infection
o Others
By Region
o North America
U.S.
Canada
Mexico
o Europe
France
Germany
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key market players
The key players operating in this market include
Allergan Plc
Bristol-Myers Squibb Company
Lupin Limited
Sanofi
Novartis International AG
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck & Co., Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Chapter: 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter: 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top winning strategies
3.3.1. Top Winning Strategies, by year, 2015-2018*
3.3.2. Top Winning Strategies, by development, 2015-2018* (%)
3.3.3. Top Winning Strategies, by company, 2015-2018*
3.3.4. Market Dynamics
3.3.5. Drivers
3.3.5.1. Surge in incidence of infectious diseases
3.3.5.2. Increase in R&D activities for the development of combination drugs
3.3.5.3. Rise in funding for the development of antibiotics
3.3.6. Restraints
3.3.6.1. Side effects associated with cephalosporin
3.3.6.2. Antibiotic resistance to cephalosporin
3.3.7. Opportunities
3.3.7.1. Lucrative opportunities in the emerging economies
3.4. Market Share Analysis, 2017
3.5. Porters Five Forces Analysis
3.6. Novel Molecules in Cephalosporin Market
3.6.1. Ceftazidime
3.6.2. Cefuroxime
3.7. Combination Therapies in Cephalosporin Market
Chapter: 4: CEPHALOSPORIN MARKET, BY GENERATION
4.1. Overview
4.1.1. Market size and forecast
4.2. First-Generation Cephalosporin
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. Second-Generation Cephalosporin
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. Third-Generation Cephalosporin
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. Fourth-Generation Cephalosporin
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. Fifth-Generation Cephalosporin
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
Chapter: 5: CEPHALOSPORIN MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Branded Cephalosporin drugs
5.2.1. Market size and forecast
5.3. Generic Cephalosporin Drugs
5.3.1. Market size and forecast
Chapter: 6: CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cephaloshorin Injections
6.2.1. Market size and forecast
6.3. Oral Cephalosporin Drugs
6.3.1. Market size and forecast
Chapter: 7: CEPHALOSPORIN MARKET, BY APPLICATION
7.1. Overview
7.1.1. Market size and forecast
7.2. Respiratory Tract Infection
7.2.1. Market size and forecast
7.3. Skin Infection
7.3.1. Market size and forecast
7.4. Ear Infection
7.4.1. Market size and forecast
7.5. Urinary Tract Infection
7.5.1. Market size and forecast
7.6. Sexually Transmitted Infection
7.6.1. Market size and forecast
7.7. Others
7.7.1. Market size and forecast
Chapter: 8: CEPHALOSPORIN MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends
8.2.2. Growth factors and opportunities
8.2.3. North America cephalosporin market by country
8.2.3.1. U.S.
8.2.3.1.1. U.S. cephalosporin market by generation
8.2.3.1.2. U.S. cephalosporin market by type
8.2.3.1.3. U.S. cephalosporin market by route of drug administration
8.2.3.1.4. U.S. cephalosporin market by application
8.2.3.2. Canada
8.2.3.2.1. Canada cephalosporin market by generation
8.2.3.2.2. Canada cephalosporin market by type
8.2.3.2.3. Canada cephalosporin market by route of drug administration
8.2.3.2.4. Canada cephalosporin market by application
8.2.3.3. Mexico
8.2.3.3.1. Mexico cephalosporin market by generation
8.2.3.3.2. Mexico cephalosporin market by type
8.2.3.3.3. Mexico cephalosporin market by route of drug administration
8.2.3.3.4. Mexico cephalosporin market by application
8.2.4. North America cephalosporin market by generation
8.2.5. North America cephalosporin market by type
8.2.6. North America cephalosporin market by route of drug administration
8.2.7. North America cephalosporin market by application
8.3. Europe
8.3.1. Key market trends
8.3.2. Growth factors and opportunities
8.3.3. Europe cephalosporin market by country
8.3.3.1. Germany
8.3.3.1.1. Germany cephalosporin market by generation
8.3.3.1.2. Germany cephalosporin market by type
8.3.3.1.3. Germany cephalosporin market by route of drug administration
8.3.3.1.4. Germany cephalosporin market by application
8.3.3.2. France
8.3.3.2.1. France cephalosporin market by generation
8.3.3.2.2. France cephalosporin market by type
8.3.3.2.3. France cephalosporin market by route of drug administration
8.3.3.2.4. France cephalosporin market by application
8.3.3.3. UK
8.3.3.3.1. UK cephalosporin market by generation
8.3.3.3.2. UK cephalosporin market by type
8.3.3.3.3. UK cephalosporin market by route of drug administration
8.3.3.3.4. UK cephalosporin market by application
8.3.3.4. Italy
8.3.3.4.1. Italy cephalosporin market by generation
8.3.3.4.2. Italy cephalosporin market by type
8.3.3.4.3. Italy cephalosporin market by route of drug administration
8.3.3.4.4. Italy cephalosporin market by application
8.3.3.5. Spain
8.3.3.5.1. Spain cephalosporin market by generation
8.3.3.5.2. Spain cephalosporin market by type
8.3.3.5.3. Spain cephalosporin market by route of drug administration
8.3.3.5.4. Spain cephalosporin market by application
8.3.3.6. Rest of Europe
8.3.3.6.1. Rest of Europe cephalosporin market by generation
8.3.3.6.2. Rest of Europe cephalosporin market by type
8.3.3.6.3. Rest of Europe cephalosporin market by route of drug administration
8.3.3.6.4. Rest of Europe cephalosporin market by application
8.3.4. Europe cephalosporin market by generation
8.3.5. Europe cephalosporin market by type
8.3.6. Europe cephalosporin market by route of drug administration
8.3.7. Europe cephalosporin market by application
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Growth factors and opportunities
8.4.3. Asia-Pacific cephalosporin market by country
8.4.3.1. Japan
8.4.3.1.1. Japan cephalosporin market by generation
8.4.3.1.2. Japan cephalosporin market by type
8.4.3.1.3. Japan cephalosporin market by route of drug administration
8.4.3.1.4. Japan cephalosporin market by application
8.4.3.2. China
8.4.3.2.1. China cephalosporin market by generation
8.4.3.2.2. China cephalosporin market by type
8.4.3.2.3. China cephalosporin market by route of drug administration
8.4.3.2.4. China cephalosporin market by application
8.4.3.3. India
8.4.3.3.1. India cephalosporin market by generation
8.4.3.3.2. India cephalosporin market by type
8.4.3.3.3. India cephalosporin market by route of drug administration
8.4.3.3.4. India cephalosporin market by application
8.4.3.4. Australia
8.4.3.4.1. Australia cephalosporin market by generation
8.4.3.4.2. Australia cephalosporin market by type
8.4.3.4.3. Australia cephalosporin market by route of drug administration
8.4.3.4.4. Australia cephalosporin market by application
8.4.3.5. South Korea
8.4.3.5.1. South Korea cephalosporin market by generation
8.4.3.5.2. South Korea cephalosporin market by type
8.4.3.5.3. South Korea cephalosporin market by route of drug administration
8.4.3.5.4. South Korea cephalosporin market by application
8.4.3.6. Rest of Asia-Pacific
8.4.3.6.1. Rest of Asia-Pacific cephalosporin market by generation
8.4.3.6.2. Rest of Asia-Pacific cephalosporin market by type
8.4.3.6.3. Rest of Asia-Pacific cephalosporin market by route of drug administration
8.4.3.6.4. Rest of Asia-Pacific cephalosporin market by application
8.4.4. Asia-Pacific cephalosporin market by generation
8.4.5. Asia-Pacific cephalosporin market by type
8.4.6. Asia-Pacific cephalosporin market by route of drug administration
8.4.7. Asia-Pacific cephalosporin market by application
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Growth factors and opportunities
8.5.3. LAMEA cephalosporin market by country
8.5.3.1. Brazil
8.5.3.1.1. Brazil cephalosporin market by generation
8.5.3.1.2. Brazil cephalosporin market by type
8.5.3.1.3. Brazil cephalosporin market by route of drug administration
8.5.3.1.4. Brazil cephalosporin market by application
8.5.3.2. South Africa
8.5.3.2.1. South Africa cephalosporin market by generation
8.5.3.2.2. South Africa cephalosporin market by type
8.5.3.2.3. South Africa cephalosporin market by route of drug administration
8.5.3.2.4. South Africa cephalosporin market by application
8.5.3.3. Saudi Arabia
8.5.3.3.1. Saudi Arabia cephalosporin market by generation
8.5.3.3.2. Saudi Arabia cephalosporin market by type
8.5.3.3.3. Saudi Arabia cephalosporin market by route of drug administration
8.5.3.3.4. Saudi Arabia cephalosporin market by application
8.5.3.4. Rest of LAMEA
8.5.3.4.1. Rest of LAMEA cephalosporin market by generation
8.5.3.4.2. Rest of LAMEA cephalosporin market by type
8.5.3.4.3. Rest of LAMEA cephalosporin market by route of drug administration
8.5.3.4.4. Rest of LAMEA cephalosporin market by application
8.5.4. LAMEA cephalosporin market by generation
8.5.5. LAMEA cephalosporin market by type
8.5.6. LAMEA cephalosporin market by route of drug administration
8.5.7. LAMEA cephalosporin market by application
Chapter: 9: COMPANY PROFILES
9.1. Allergan Plc.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments
9.2. Bristol-Myers Squibb Company
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Product portfolio
9.2.5. Business performance
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments
9.4. GlaxoSmithKline plc
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance
9.5. Lupin Limited (Lupin Pharmaceuticals, Inc.)
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments
9.7. Novartis International AG (Sandoz)
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sanofi
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
